Inactivation of p90RSK3 acts synergistically with EGFR-inhibition, thus posing a potential synthetic lethal drug target for overcoming PI3K-inhibitor resistance in breast cancer [27, 28]. Here, RPS6KA2 is linked to breast carcinoma.